← All trials
NCT05179733
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 2, 2022
- Primary completion
- Dec 25, 2025
- Completion date
- Dec 25, 2025
- First posted
- Jan 5, 2022
- Last posted
- Dec 23, 2022
- Enrollment
- 280
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiao Tong UniversityLead sponsor
- Nantong UniversityCollaborator
- Changzhou No.2 People's HospitalCollaborator
- Fujian Medical UniversityCollaborator
- China Medical UniversityCollaborator
- Henan Provincal People's HospitalCollaborator
- Fudan UniversityCollaborator
- Huai'an First People's HospitalCollaborator
- Central South UniversityCollaborator
- United States NavyCollaborator
- Ningbo No. 1 HospitalCollaborator
- Nanjing Medical UniversityCollaborator
- Shandong UniversityCollaborator
- Jiao Tong UniversityReponsible party - principal investigator
- Shandong Provincial HospitalCollaborator
- Shanghai Fengxian District Central HospitalCollaborator
- Zhejiang UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Xuzhou Medical UniversityCollaborator
- Nanjing UniversityCollaborator
- Nanchang UniversityCollaborator
- Jinlin UniversityCollaborator
- The First People's Hospital of Changde CityCollaborator
- Nanjing Medical UniversityCollaborator
- Dalian Medical UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Jiao Tong UniversityCollaborator
- Yanshi People’s HospitalCollaborator
- Jiao Tong UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.